Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 2
2010 2
2011 2
2012 3
2013 3
2014 3
2015 2
2016 3
2017 3
2018 2
2019 2
2020 4
2021 14
2022 14
2023 7
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Results by year

Filters applied: . Clear all
Page 1
Customizably designed multibodies neutralize SARS-CoV-2 in a variant-insensitive manner.
Abreu C, Ortega C, Olivero-Deibe N, Carrión F, Gaete-Argel A, Valiente-Echeverría F, Soto-Rifo R, Milan Bonotto R, Marcello A, Pantano S. Abreu C, et al. Among authors: valiente echeverria f. Front Immunol. 2023 Aug 10;14:1226880. doi: 10.3389/fimmu.2023.1226880. eCollection 2023. Front Immunol. 2023. PMID: 37638023 Free PMC article.
Humoral and cellular response induced by a second booster of an inactivated SARS-CoV-2 vaccine in adults.
Méndez C, Peñaloza HF, Schultz BM, Piña-Iturbe A, Ríos M, Moreno-Tapia D, Pereira-Sánchez P, Leighton D, Orellana C, Covarrubias C, Gálvez NMS, Soto JA, Duarte LF, Rivera-Pérez D, Vázquez Y, Cabrera A, Bustos S, Iturriaga C, Urzua M, Navarrete MS, Rojas Á, Fasce RA, Fernández J, Mora J, Ramírez E, Gaete-Argel A, Acevedo M, Valiente-Echeverría F, Soto-Rifo R, Weiskopf D, Grifoni A, Sette A, Zeng G, Meng W; CoronaVac03CL Study Group; González-Aramundiz JV, González PA, Abarca K, Melo-González F, Bueno SM, Kalergis AM. Méndez C, et al. Among authors: valiente echeverria f. EBioMedicine. 2023 May;91:104563. doi: 10.1016/j.ebiom.2023.104563. Epub 2023 Apr 24. EBioMedicine. 2023. PMID: 37099842 Free PMC article.
Impact of homologous and heterologous boosters in neutralizing antibodies titers against SARS-CoV-2 Omicron in solid-organ transplant recipients.
Gaete-Argel A, Saavedra-Alarcón V, Sauré D, Alonso-Palomares L, Acevedo ML, Alarcón M, Bueno SM, Kalergis AM, Soto-Rifo R, Valiente-Echeverría F, Cortes CP. Gaete-Argel A, et al. Among authors: valiente echeverria f. Front Immunol. 2023 Mar 13;14:1135478. doi: 10.3389/fimmu.2023.1135478. eCollection 2023. Front Immunol. 2023. PMID: 36999018 Free PMC article. Clinical Trial.
COVID-19 lateral flow IgG seropositivity and serum neutralising antibody responses after primary and booster vaccinations in Chile: a cross-sectional study.
Sauré D, O'Ryan M, Torres JP, Zuñiga M, Soto-Rifo R, Valiente-Echeverría F, Gaete-Argel A, Neira I, Saavedra V, Acevedo ML, Archila C, Acuña F, Rain M, Basso LJ. Sauré D, et al. Among authors: valiente echeverria f. Lancet Microbe. 2023 Mar;4(3):e149-e158. doi: 10.1016/S2666-5247(22)00290-7. Epub 2023 Jan 27. Lancet Microbe. 2023. PMID: 36716754 Free PMC article.
Author Correction: Differential neutralizing antibody responses elicited by CoronaVac and BNT162b2 against SARS-CoV-2 Lambda in Chile.
Acevedo ML, Gaete-Argel A, Alonso-Palomares L, de Oca MM, Bustamante A, Gaggero A, Paredes F, Cortes CP, Pantano S, Martínez-Valdebenito C, Angulo J, Le Corre N, Ferrés M, Navarrete MA, Valiente-Echeverría F, Soto-Rifo R. Acevedo ML, et al. Among authors: valiente echeverria f. Nat Microbiol. 2023 Feb;8(2):360. doi: 10.1038/s41564-023-01324-y. Nat Microbiol. 2023. PMID: 36658398 Free PMC article. No abstract available.
Neutralizing antibodies induced by homologous and heterologous boosters in CoronaVac vaccines in Chile.
Acevedo J, Acevedo ML, Gaete-Argel A, Araos R, Gonzalez C, Espinoza D, Rivas S, Pizarro P, Jarpa S, Soto-Rifo R, Jara A, Valiente-Echeverría F. Acevedo J, et al. Among authors: valiente echeverria f. Clin Microbiol Infect. 2023 Apr;29(4):541.e1-541.e7. doi: 10.1016/j.cmi.2022.11.017. Epub 2022 Nov 25. Clin Microbiol Infect. 2023. PMID: 36436704 Free PMC article. Clinical Trial.
Inactivated Vaccine-Induced SARS-CoV-2 Variant-Specific Immunity in Children.
Soto JA, Melo-González F, Gutierrez-Vera C, Schultz BM, Berríos-Rojas RV, Rivera-Pérez D, Piña-Iturbe A, Hoppe-Elsholz G, Duarte LF, Vázquez Y, Moreno-Tapia D, Ríos M, Palacios PA, Garcia-Betancourt R, Santibañez Á, Pacheco GA, Mendez C, Andrade CA, Silva PH, Diethelm-Varela B, Astudillo P, Calvo M, Cárdenas A, González M, Goldsack M, Gutiérrez V, Potin M, Schilling A, Tapia LI, Twele L, Villena R, Grifoni A, Sette A, Weiskopf D, Fasce RA, Fernández J, Mora J, Ramírez E, Gaete-Argel A, Acevedo ML, Valiente-Echeverría F, Soto-Rifo R, Retamal-Díaz A, Muñoz-Jofré N; PedCoronaVac03CL Study Group,; Meng X, Xin Q, Alarcón-Bustamante E, González-Aramundiz JV, Le Corre N, Álvarez-Figueroa MJ, González PA, Abarca K, Perret C, Carreño LJ, Bueno SM, Kalergis AM. Soto JA, et al. Among authors: valiente echeverria f. mBio. 2022 Dec 20;13(6):e0131122. doi: 10.1128/mbio.01311-22. Epub 2022 Nov 16. mBio. 2022. PMID: 36383021 Free PMC article.
Differences in the immune response elicited by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial.
Gálvez NMS, Pacheco GA, Schultz BM, Melo-González F, Soto JA, Duarte LF, González LA, Rivera-Pérez D, Ríos M, Berrios RV, Vázquez Y, Moreno-Tapia D, Vallejos OP, Andrade CA, Hoppe-Elsholz G, Iturriaga C, Urzua M, Navarrete MS, Rojas Á, Fasce R, Fernández J, Mora J, Ramírez E, Gaete-Argel A, Acevedo ML, Valiente-Echeverría F, Soto-Rifo R, Weiskopf D, Grifoni A, Sette A, Zeng G, Meng W; CoronaVacCL03 Study Group; González-Aramundiz JV, Johnson M, Goldblatt D, González PA, Abarca K, Bueno SM, Kalergis AM. Gálvez NMS, et al. Among authors: valiente echeverria f. Elife. 2022 Oct 13;11:e81477. doi: 10.7554/eLife.81477. Elife. 2022. PMID: 36226829 Free PMC article. Clinical Trial.
A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern.
Schultz BM, Melo-González F, Duarte LF, Gálvez NMS, Pacheco GA, Soto JA, Berríos-Rojas RV, González LA, Moreno-Tapia D, Rivera-Pérez D, Ríos M, Vázquez Y, Hoppe-Elsholz G, Andrade-Parra CA, Vallejos OP, Piña-Iturbe A, Iturriaga C, Urzua M, Navarrete MS, Rojas Á, Fasce R, Fernández J, Mora J, Ramírez E, Gaete-Argel A, Acevedo ML, Valiente-Echeverría F, Soto-Rifo R, Weiskopf D, Grifoni A, Sette A, Zeng G, Meng W; CoronaVac03CL Study Group; González-Aramundiz JV, González PA, Abarca K, Kalergis AM, Bueno SM. Schultz BM, et al. Among authors: valiente echeverria f. mBio. 2022 Aug 30;13(4):e0142322. doi: 10.1128/mbio.01423-22. Epub 2022 Aug 10. mBio. 2022. PMID: 35946814 Free PMC article.
62 results